Covid Vaccine Race

Qatar has the highest mRNA vaccine coverage in the world, but their vaccinated population is experiencing significant waning in vaccine efficacy, leading to breakthrough infections.

US federal health agencies are recommending an additional shot for this diverse patient population, and here on some insights about vaccine efficacy and breakthrough infections in these groups.

This study confirmed reports from the CDC and Israel Ministry of Health that found the Pfizer-BioNTech vaccine waned after 6 months.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

Investigators examined asymptomatic infection and the duration of viral shedding in symptomatic breakthrough infections in a phase 3 study with the AZD1222 COVID-19 vaccine.

An expert explains the science of vaccine- and infection-induced immunity, and how it informs the timeline of COVID-19 outbreaks this year.

A new study breaks down the risk prediction of death or hospitalization related to COVID-19 in adults following their vaccination.

The companies will be seeking emergency authorization for a lighter-dose mRNA vaccine for children aged 5 to <12 years old.

Data finds low risk for anaphylaxis, myocarditis, and other potential complications.

Extended findings from blinded mRNA-1273 vaccine pivotal trial include efficacy across subgroups, including elderly and with coexisting conditions.

Only about 60% of Americans have immunity, a number too low to protect the country through “herd immunity,” according to a new report.

In a departure from the independent APIC advisors, CDC Director Rochelle Walensky, MD, has decided to recommend boosters for people in high-risk occupations.

The Advisory Committee on Immunization Practices posed a series of 4 questions related to a potential third shot of the Pfizer-BioNTech COVID-19 vaccine in various populations.

A third dose booster vaccination given to persons 60 years of age or over in Israel was confirmed to lower their rate of COVID-19 infection compared to a 2-dose regimen.

New research shows COVID-19 mortality risk to be more nuanced than previous studies.

The federal agency will grant an Emergency Use Authorization (EUA) for the third dose for seniors, those deemed high risk, and those with jobs that put them at risk of infection.

A presentation of available third-dose data suggest the adverse event rate is consistent with that observed with second doses.

Patients with cancer now have official confirmation that vaccinating against COVID-19 will protect them from contracting the virus.

With the Delta cases surging in recent weeks, and the upcoming flu season almost upon us, here is a glimpse of what providers and the public can expect when both viruses are circulating.

After two doses of the Pfizer-BioNTech COVID-19 vaccine, 83% of allogeneic hematopoietic stem cell transplant recipients showed positive antibody response.

Preprint data from a real-world evidence assessment, as well as preliminary reports from a 2-dose trial, support the company's pursuit for FDA authorization of a second COVID-19 vaccine dose.

A smaller dosage was used and with their results the two companies plan to submit their data to governmental regulatory agencies around the world.

The Centers for Disease Control and Prevention's (CDC) VISION Network of health care systems provided data for test-negative design analysis of vaccine effectiveness in preventing COVID-19 acute admissions.

After voting against recommendation of a booster dose for people 16 years and older, the committee created a new question to vote on an EUA for a booster dose for people 65 years and older and those at high risk of COVID-19. They voted 18-0 in favor.

The VRBPAC voted 16-2 on Friday afternoon on the question they were presented.

A Food and Drug Administration (FDA) committee will discuss this topic as it pertains to the potential approval of a third dose of the Pfizer-BioNTech COVID-19 vaccine. The results of this meeting could have ramifications for the Biden Administration’s COVID-19 health policy.

Based on recent studies, the company sees benefits in administering booster doses.

Recent data shows that all three COVID-19 vaccines being administered in the United States are showing high rates of vaccine effectiveness (VE).

Though efficacy waned over months, protection from symptomatic and severe COVID-19 remained significant, with no new adverse event risks observed.

In a recent speech, Pfizer’s CFO says it might be a matter of weeks for submitting an application for children 6 months to 5 years old.